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February 2016 Abstracts S51The Ontario Clinical Oncology Group (OCOG) – ALMERA
trial (NCT02186847) is a Canadian multicenter ran-
domized phase II trial funded by the Canadian Institute
for Health Research, which is designed to examine
whether metformin has chemo-radio-sensitization ac-
tivity as well as activity as a single agent in advanced
localized NSCLC. A total of 94 patients will be random-
ized in this screening trial to standard CRT with or
without treatment with 2000mg of metformin, which is
delivered during CRT (2 cycles of cisplatin based
chemotherapy, concurrent with chest RT of 63 Gy in 30
fractions) but continues also as a single agent for a total
of 12 months.
ALMERA is designed to detect a 20% improvement in
lung cancer progression free survival at 12 months. This
trial is now open in several centers across Canada. The
primary outcome is 12 month Progression Free Survival
(PFS) and secondary outcomes include 1 and 2 y overall
survival (OAS), time to loco-regional progression, distant
progression free survival, adverse events and collection of
biospecimens for biomarker studies. These will involve
investigation of circulating serum and blood cell bio-
markers of metformin activity and tumor biomarkers such
as tumor histology, TP53, LKB1 and K-Rasmutation status.
When completed ALMERAwill provide some of the ﬁrst
prospective evidence on the potential of metformin to
improve the outcomes of standard cytotoxic therapy in
locally advanced NSCLC. Biospecimen collect will allow us
to investigate serum and tumors biomarkers ofmetformin
response. Comparison of the results of ALMERA with
other studies, like NRG-LU001, may be able to provide
evidence on the value of metformin as maintenance
therapy and assist in the design of future phase III trials
with metformin in the setting of locally advanced NSCLC.* Due to unforeseen circumstance, this poster was not presented.An integrative cross-tumors approach
identiﬁes FOSL1 as an oncogene
dependency in KRAS-driven lung
cancerAdrian Vallejo,1 Naiara Perurena,1
Elizabeth Guruceaga,1 Pawel K. Mazur,2Susana Martinez-Canarias,1 Carolina Zandueta,1
Dana Gwinn,2 Leanne C. Sayles,2 Chen-Hua Chuang,2
Jesper B. Andersen,3 Aline Bozec,4
Alejandro Sweet-Cordero,2 Julien Sage,2
Fernando Lecanda,1 Silvestre Vicent1 1Center for
Applied Medical Research, Pamplona, Spain, 2Stanford
University, Stanford, CA, 3University of Copenhagen,
Copenhagen, Denmark, 4University of Erlangen-
Nuremberg, Erlangen, GermanyThe KRAS oncogene represents a clinically-relevant
target in human cancers refractory to current thera-
pies. Thus, the identiﬁcation of molecules mediating
oncogenic KRAS effects may help implement novel
therapeutic strategies. Here we describe a new
approach integrating a cross-tumors gene-expression
screen and patient survival information to unveil KRAS
dependencies in human tumors. This strategy uncov-
ered the transcription factor FOS-like antigen 1
(FOSL1) as a critical mediator of KRAS-driven lung
tumors. FOSL1 was up-regulated in mouse and human
mutant KRAS cells and its high expression was a
marker of poor survival in patients harboring KRAS
mutations. Additionally, FOSL1 loss led to impaired
cell viability in mutant KRAS cancer cells in vitro and
in vivo and in a genetically-engineered mouse model of
Kras mutated lung adenocarcinoma. Mechanistically,
this effect involved the transcriptional down-regula-
tion of genes involved in mitosis, a pathway previously
postulated to act orthogonally to KRAS signaling,
whose high expression was associated with shortened
survival of mutant KRAS patients. Lastly, pharmaco-
logical inhibition of FOSL1 downstream targets
involved in mitosis progression had a preferential
deleterious impact on mutant KRAS tumors than wild
type. Collectively, our ﬁndings identify FOSL1 as a
critical factor in KRAS-driven tumors, thereby impli-
cating FOSL1 and downstream targets as potential
candidates for therapeutic intervention.
Supported by a 2015 Young Investigator Award by the
International Association for the Study of Lung Cancer
(IASLC).Intelligent forceps for solitary
pulmonary nodule diagnostics*
Jiri Votruba, Tomas Bruha Charles University
Hospital, Praha, Czech RepublicRecently, SPNs have become more frequently encoun-
tered in pulmonary medicine. Therefore, an efﬁcient and
reliable method for detecting SPNs based on their
morphological characteristics is needed.
We have validated the efﬁcacy of near infrared (NIR)
spectroscopy based catheter connected to biopsy forceps
for solitary pulmonary nodule (SPN) diagnostics.
Methods: Between May 2014 and May 2015 we exam-
ined 20 male and 18 female patients having a median
age of 62 years with positron emission tomography-
computed tomography ﬁndings of metabolically active
SPN between 1, 5 to 3 cm in diameter.
Fluoroscopic guidance was combined with a radial
EBUS (without guide-sheath). In the case radial EBUS
S52 Journal of Thoracic Oncology Vol. 11 No. 2Sconclusively showed catheter position in the centre of
SPN (26 cases) NIR spectroscopy probe based forceps
were placed at the same place in order to gather tissue
information. Mean measurement time was less than one
minute after establishing ideal position. Results of
spectroscopy measurements from NIR spectroscopy
were obtained as differences between spectral charac-
teristics of normal tissue (same side, different lobe) to
SPN tissue.
Results: The results are expressed as sensitivity of NIR
spectroscopy towards EBUS navigated biopsies. Statisti-
cal analysis of the results showed very high sensitivity
for NIR spectroscopy in conﬁrmation of SPN tissue. From
26 EBUS positive visualisations of SPN there were 26
correct discriminations of SPN tissue, leading to 23
conclusive histological ﬁndings.
Conclusions: Every conﬁrmatory method brings
different information about tissue. EBUS describes vol-
ume of the SPN and gives valuable information about the
position of catheter in the SPN. NIR spectroscopy brings
information about biochemical/ optical characteristics of
the tissues. Prototype of intelligent NIR based forceps
showed good discriminative ability in the diagnosis of
SPN.* Due to unforeseen circumstance, this poster was not presented.Characterization of programmed cell
death-1 ligand (PD-L1) expression in
circulating tumor cells (CTCs) of lung
cancerRachel Krupa, David Lu, Ryon Graf,
Jessica Louw, Lyndsey Dugan,
Adam Jendrisak, Kelly Bethel, Yipeng Wang,
Dena Marrinucci, Ryan Dittamore Epic Sciences, San
Diego, CA
Introduction: The programmed cell death-1/pro-
grammed cell death-1 ligand (PD-1/PD-L1) pathway
plays a key role in tumor immune invasion. Emerging
literature suggests that PD-L1 over-expression on solid
tumor tissue, including lung cancer, is associated with
PD-1/PD-L1 immunotherapy efﬁcacy. Epic Sciences has
developed circulating tumor cells (CTCs) based PD-L1
assay, and we sought to evaluate the feasibility of
detecting PD-L1 biomarker in lung cancer CTCs.
Methods: 74 samples from newly diagnosed lung cancer
patients prior to therapy were recruited and blood
specimens were collected and shipped to Epic Sciences.
All nucleated cells were plated onto glass slides and
subjected to immunoﬂuorescence (IF) staining and CTCidentiﬁcation by ﬂuorescent scanners and algorithmic
analysis. CK(þ) CTCs(CKþ CD45- w/intact DAPI nuclei
and morphologically distinct), apoptotic CTCs (CKþ,
CD45-, non-intact nuclei), CTC Clusters (two or more
CTCs together) and CK(-) CTCs (CK-, CD45-, intact and
distinct) were identiﬁed. Samples were characterized
with PD-L1 IF to assess expression.
Results: Assays for the PD-L1 protein were developed
and speciﬁcity conﬁrmed utilizing Colo205 (negative
control) and H820 (high PD-L1 expression) cells spiked
into donor blood and run through the Epic Assay. Addi-
tionally, analysis of Colo205, A549, and SU-DHL-1 cell
lines show increased differential expression when cells
were exposed to Interferon gamma. PD-L1 protein
expression was visualized in CTCs of 15/74 (20%) pa-
tients with lung cancer. PD-L1 expression was seen in
CK(þ) CTCs, CK(-) CTCs, apoptotic CTCs, andCTCClusters.
Conclusion: PD-L1 protein assessment in CTC sub-
populations from lung cancer patients at diagnosis is
feasible on the Epic CTC platform. The test demonstrates
analytical sensitivity and speciﬁcity and may aid in the
identiﬁcation of patients suitable for clinical trial studies
with novel anti-PD-1 or anti-PD-L1 therapies. The
assessment of PD-L1 expression from a circulating
marker could enable longitudinal and pharmacodynamic
analysis in response to PD-1 axis blockade in patients.Validation of DNA methylation marker
SHOX2 and PTGER4 for detection of
lung cancer in plasmaAnne Schlegel, Oliver Hasinger,
Thomas König, Gunter Weiss Epigenomics AG,
Berlin, Germany
Introduction: Annual screening for lung cancer (LC)
with low-dose computed tomography (LDCT) has been
shown to reduce mortality in a speciﬁc group of high risk
individuals. At the same time some controversy builds
around the substantial rate of false positive ﬁndings of
the method. Thus, research focuses on two questions: 1)
Whom to screen? Additions to and reﬁnements of the
group of high risk individuals who potentially beneﬁt
from LDCT screening. 2) What to do with a nodule?
Distinguish a malignant nodule from a benign one. Here,
we report on a panel of two DNA methylation markers,
SHOX2 and PTGER4, with the potential to address either
or both of the aforementioned questions.
Material and Methods: A triplex real-time PCR assay
was developed to assess the level of methylated DNA of
genes SHOX2 and PTGER4 in bisulﬁte converted DNA
containing ACTB as internal control. DNA was extracted,
